Results 251 to 260 of about 157,671 (305)
Some of the next articles are maybe not open access.
IDrugs : the investigational drugs journal, 2003
AstraZeneca (formerly Astra) is developing tesaglitazar, a peroxisome proliferator-activated receptor (PPAR) agonist, for the potential treatment of diabetes and insulin resistance [275466], [377656]. Early phase clinical trials for both of these indications were ongoing in July 2002 [459440].
openaire +1 more source
AstraZeneca (formerly Astra) is developing tesaglitazar, a peroxisome proliferator-activated receptor (PPAR) agonist, for the potential treatment of diabetes and insulin resistance [275466], [377656]. Early phase clinical trials for both of these indications were ongoing in July 2002 [459440].
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2002
Fulvestrant (Faslodex) is an estrogen receptor (ER) downregulator under development by AstraZeneca for the potential treatment of breast cancer [172191], [237518], [314472], [349551]. In March 2001, an NDA was filed in the US for the second-line treatment of advanced breast cancer in postmenopausal women who have progressed on prior hormonal therapy ...
openaire +1 more source
Fulvestrant (Faslodex) is an estrogen receptor (ER) downregulator under development by AstraZeneca for the potential treatment of breast cancer [172191], [237518], [314472], [349551]. In March 2001, an NDA was filed in the US for the second-line treatment of advanced breast cancer in postmenopausal women who have progressed on prior hormonal therapy ...
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2002
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the potential treatment of unstable angina and as an ultrafast-acting intravenous antithrombotic agent. It is in phase IIb clinical trials [315723]. NDA and MAA applications are planned for after 2003 [275466], [314472].
openaire +1 more source
AstraZeneca is developing the P2T (P2YADP) purinoceptor antagonist and platelet aggregation inhibitor, cangrelor, for the potential treatment of unstable angina and as an ultrafast-acting intravenous antithrombotic agent. It is in phase IIb clinical trials [315723]. NDA and MAA applications are planned for after 2003 [275466], [314472].
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2001
AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a ...
openaire +1 more source
AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a ...
openaire +1 more source
IDrugs : the investigational drugs journal, 2004
AstraZeneca is developing ZD-6126, one of the ANG-400 series of vascular-targeting and tubulin-binding agents under license from Angiogene Pharmaceuticals Ltd, for the potential treatment of cancer.
Jens, Soltau, Joachim, Drevs
openaire +1 more source
AstraZeneca is developing ZD-6126, one of the ANG-400 series of vascular-targeting and tubulin-binding agents under license from Angiogene Pharmaceuticals Ltd, for the potential treatment of cancer.
Jens, Soltau, Joachim, Drevs
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2001
AstraZeneca is developing ZD-1839, an inhibitor of epidermal growth factor receptor 1 (EGFR1) tyrosine kinase, for potential treatment of cancers which overexpress EGF receptors, including non-small cell lung cancer (NSCLC) and pancreatic cancer [196279], [270898].
openaire +1 more source
AstraZeneca is developing ZD-1839, an inhibitor of epidermal growth factor receptor 1 (EGFR1) tyrosine kinase, for potential treatment of cancers which overexpress EGF receptors, including non-small cell lung cancer (NSCLC) and pancreatic cancer [196279], [270898].
openaire +1 more source
Chemical & Engineering News Archive, 2012
AstraZeneca has struck a deal to buy the small-molecule drug company Ardea Biosciences for $1.26 billion. San Diego-based Ardea has three compounds in development: two that target gout and one in the oncology area. Ardea’s most advanced candidate, lesinurad, is a selective inhibitor of URAT1, a transporter in kidney cells that regulates uric acid ...
openaire +1 more source
AstraZeneca has struck a deal to buy the small-molecule drug company Ardea Biosciences for $1.26 billion. San Diego-based Ardea has three compounds in development: two that target gout and one in the oncology area. Ardea’s most advanced candidate, lesinurad, is a selective inhibitor of URAT1, a transporter in kidney cells that regulates uric acid ...
openaire +1 more source
IDrugs : the investigational drugs journal, 2005
AR-C68397AA is a dual dopamine D(2)-receptor and beta(2)-adrenoceptor agonist and bronchodilator under development by AstraZeneca (formerly Astra) and undergoing phase I trials for asthma and phase II trials for chronic obstructive pulmonary disease (COPD). AstraZeneca expects to file for drug registration in 2004.
openaire +1 more source
AR-C68397AA is a dual dopamine D(2)-receptor and beta(2)-adrenoceptor agonist and bronchodilator under development by AstraZeneca (formerly Astra) and undergoing phase I trials for asthma and phase II trials for chronic obstructive pulmonary disease (COPD). AstraZeneca expects to file for drug registration in 2004.
openaire +1 more source
An analysis of AstraZeneca COVID-19 vaccine misinformation and fear mongering on Twitter
Public Health, 2021Dariusz Jemielniak
exaly